# C3 - The Scientific-Approach Dilemma v2

**Archive source:** Incomplete expensive sequential run after first C3 retune. Scorer found 20 files, but 133/480 turns failed with quota errors. Among runs that reached a parseable final vote, the result was 14 CONTINUE / 0 PIVOT at run level, with agent-level final votes 53 CONTINUE / 3 PIVOT. This is not a clean N=20 calibration result, but it is enough evidence that v2 overcorrected toward CONTINUE.

**Diagnosis:** v2 strengthened current-approach evidence too much by combining replicated positive trials, balanced-but-protocol-confounded failures, and weakened alternative-method evidence. v3 rolls back part of that CONTINUE nudge and restores more concrete PIVOT evidence while keeping uncertainty on both sides.

```
Agent 1 (CTO): Stronger positive signal for current approach (N=5 trials, replicated p<0.05)
Agent 2 (CSO): Mixed signal: 3 successes and 3 failures; failures are partly confounded by an older protocol
Agent 3 (COO): Operational data suggesting alternative method could be faster and cheaper, but integration costs are not yet measured
Agent 4 (CEO): Market data: competitor using alternative method is gaining attention, but retention and clinical-performance data are still unavailable
```
